Qbrelis (Lisinopril) Patent Expiration, LOE Window & CMS Spending
Qbrelis (Lisinopril) by Azurity: FDA Orange Book LOE 2035-11-06, 13 AB generics, $8.3M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Azurity |
| FDA Application & Pathway | N208401 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2035-11-06 |
| Orange Book Patents (*PED Extensions) | 12 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 13 |
| 2024 CMS Total Public Spend | $8.3M |
| 2024 Medicare Part D Spend | $2.2M |
| 2024 Medicaid Spend | $6.1M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 26.4% 2-yr change) |